Abstract |
Telomerase activity is repressed in normal human somatic cells, but is activated in most cancers, suggesting that telomerase may be an important target for cancer therapy. Agents that interact selectively with telomerase are anticipated to exert specific action on cancer cells. In this study, we evaluated maleimide derivatives for their potency and selectivity of telomerase inhibition. Among the several N-substituted derivatives of maleimide tested, N-(1-Pyrenyl) maleimide was shown to exert the greatest inhibition of telomerase in a cell free system, with an IC50 value of 0.25 μM. Importantly, we demonstrated that N-(1-pyrenyl) maleimide induces apoptosis in Jurkat T cells and displays the greatest differential cytotoxicity against hematopoietic cancer cells. These results suggest that N-(1-pyrenyl) maleimide is an attractive maleimide to be tested and developed as anti- cancer drug.
|
Authors | Pei-Rong Huang, Yuan-Ming Yeh, Chia-Chu Pao, Chi-Yuan Chen, Tzu-Chien V Wang |
Journal | Molecular biology reports
(Mol Biol Rep)
Vol. 39
Issue 9
Pg. 8899-905
(Sep 2012)
ISSN: 1573-4978 [Electronic] Netherlands |
PMID | 22707200
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Enzyme Inhibitors
- Maleimides
- N-(3-pyrene)maleimide
- Telomerase
|
Topics |
- Apoptosis
(drug effects)
- Cell-Free System
- Enzyme Activation
(drug effects)
- Enzyme Inhibitors
(chemistry, pharmacology, toxicity)
- Humans
- Inhibitory Concentration 50
- Jurkat Cells
- Leukocytes, Mononuclear
(drug effects)
- Maleimides
(chemistry, pharmacology, toxicity)
- Telomerase
(antagonists & inhibitors)
|